GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » EBIT

Personalis (Personalis) EBIT : $-92.46 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis EBIT?

Personalis's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-12.95 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-92.46 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Personalis's annualized ROC % for the quarter that ended in Mar. 2024 was -73.49%. Personalis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -68.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Personalis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -428.14%.


Personalis EBIT Historical Data

The historical data trend for Personalis's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis EBIT Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -23.94 -41.22 -65.03 -113.07 -108.10

Personalis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.60 -23.88 -29.06 -26.57 -12.95

Competitive Comparison of Personalis's EBIT

For the Diagnostics & Research subindustry, Personalis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Personalis's EV-to-EBIT falls into.



Personalis EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis  (NAS:PSNL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Personalis's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-75.52 * ( 1 - -0.05% )/( (109.774 + 95.855)/ 2 )
=-75.55776/102.8145
=-73.49 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=225.099 - 15.815 - ( 114.179 - max(0, 47.234 - 146.744+114.179))
=109.774

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Personalis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-51.808/( ( (75.218 + max(-5.262, 0)) + (72.044 + max(3.11, 0)) )/ 2 )
=-51.808/( ( 75.218 + 75.154 )/ 2 )
=-51.808/75.186
=-68.91 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.73 + 5.661 + 9.174) - (15.815 + 3.8 + 18.212)
=-5.262

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(11.345 + 4.975 + 8.7) - (10.355 + 3.881 + 7.674)
=3.11

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Personalis's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-92.457/21.595
=-428.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis EBIT Related Terms

Thank you for viewing the detailed overview of Personalis's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (Personalis) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.
Executives
Richard Chen officer: Chief Scientific Officer C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore officer: General Counsel C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana officer: Chief Financial Officer 400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall officer: President 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Kenneth J Widder director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff director C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West director, officer: President and CEO C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom director C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Myers Woodrow A Jr director 1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum director
Arif Janmohamed other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025